Similarly, exoPD-L1 in NSCLC patients inhibited CD8+ T cell activity in a dose-dependent manner, inducing CD8+ T cell apoptosis and reducing IL-2 and IFN-γ production (137). This evidence concerns the gene CD8A and non-small cell lung carcinoma.